



Office de la Propriété
Intellectuelle
du Canada

Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office

An agency of
Industry Canada

CA 2460571 A1 2003/03/27

(21) **2 460 571**

(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2001/09/14
(87) Date publication PCT/PCT Publication Date: 2003/03/27
(85) Entrée phase nationale/National Entry: 2004/03/15
(86) N° demande PCT/PCT Application No.: ES 2001/000347
(87) N° publication PCT/PCT Publication No.: 2003/024918

(51) Cl.Int.⁷/Int.Cl.⁷ C07C 233/11, C07D 241/04,
C07C 231/02

(71) Demandeur/Applicant:
MEDICHEM S.A., ES

(72) Inventeurs/Inventors:
BOSCH I LLADO, JORDI, ES;
CAMPS GARCIA, PELAYO, ES;
CONTRERAS LASCORZ, JUAN, ES;
ONRUBIA MIGUEL, MA CARMEN, ES

(74) Agent: OGILVY RENAULT

(54) Titre : COMPOSES INTERMEDIAIRES POUR LA PREPARATION DE MIRTAZAPINE ET LEURS PROCEDES DE PRODUCTION

(54) Title: INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MIRTAZAPINE AND THE PRODUCTION METHODS THEREOF

(57) Abrégé/Abstract:

The invention relates to intermediate compounds that are used for the preparation of mirtazapine and the production methods thereof. The inventive method is used to produce (+/-)-3-phenyl-1-methylpiperazine which is an important intermediate for the production of mirtazapine. Said method consists in subjecting novel compounds having general formula (I), wherein Z is a leaving group that can undergo nucleophilic displacement, to a cyclization reaction in the presence of a reducing agent. The invention also relates to a method of producing novel compounds having formula (I).



(12) SOLICITUD INTERNACIONAL PUBLICADA EN VIRTUD DEL TRATADO DE COOPERACIÓN
EN MATERIA DE PATENTES (PCT)(19) Organización Mundial de la Propiedad
Intelectual
Oficina internacional(43) Fecha de publicación internacional
27 de Marzo de 2003 (27.03.2003)

PCT

(10) Número de Publicación Internacional
WO 03/024918 A1(51) Clasificación Internacional de Patentes⁷:

C07C 233/11, 231/02, C07D 241/04

(74) Mandatarios: CURELL SUÑOL, Marcelino etc.; Pas-
seig de Gràcia, 65 bis, E-08008 Barcelona (ES).

(21) Número de la solicitud internacional: PCT/ES01/00347

(81) Estados designados (*nacional*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) Fecha de presentación internacional:

14 de Septiembre de 2001 (14.09.2001)

(25) Idioma de presentación:

español

(26) Idioma de publicación:

español

(84) Estados designados (*regional*): patente ARIPO (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), patente euroasiática (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), patente europea (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), patente OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).(71) Solicitante (*para todos los Estados designados salvo US*): MEDICHEM S.A. [ES/ES]; Fructuós Gelabert, 6-8, E-08970 Sant Joan Despí (ES).

(72) Inventores; e

(75) Inventores/Solicitantes (*para US solamente*): BOSCH I LLADÓ, Jordi [ES/ES]; Plaza Miquel Coll i Alentorn, 2, E-17003 Girona (ES). CAMPS GARCÍA, Pelayo [ES/ES]; Capitán Arenas, 17, E-08034 Barcelona (ES). CONTRERAS LASCORZ, Juan [ES/ES]; Orriols, 24, E-17460 Celrà (ES). ONRUBIA MIGUEL, M^a Carmen [ES/ES]; Pasaje del Crédito, 5, E-08002 Barcelona (ES).

Publicada:

— con informe de búsqueda internacional

Para códigos de dos letras y otras abreviaturas, véase la sección "Guidance Notes on Codes and Abbreviations" que aparece al principio de cada número regular de la Gaceta del PCT.

(54) Title: INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF MIRTAZAPINE AND THE PRODUCTION METHODS THEREOF

(54) Título: COMPUESTOS INTERMEDIOS PARA LA PREPARACIÓN DE MIRTAZAPINA Y SUS PROCEDIMIENTOS DE OBTENCIÓN

(57) Abstract: The invention relates to intermediate compounds that are used for the preparation of mirtazapine and the production methods thereof. The inventive method is used to produce (+/-)-3-phenyl-1-methylpiperazine which is an important intermediate for the production of mirtazapine. Said method consists in subjecting novel compounds having general formula (I), wherein Z is a leaving group that can undergo nucleophilic displacement, to a cyclization reaction in the presence of a reducing agent. The invention also relates to a method of producing novel compounds having formula (I).

(57) Resumen: Compuestos intermedios para la preparación de mirtazapina y sus procedimientos de obtención. Se describe un procedimiento para la obtención de -3-fenil-1-metilpiperazina, importante intermedio para la obtención de mirtazapina, que se basa en someter a una reacción de ciclación, en presencia de un agente reductor, unos nuevos compuestos de fórmula general (I) en la que Z es un grupo saliente capaz de sufrir un desplazamiento nucleofílico. Se describe también un procedimiento para la obtención de los nuevos compuestos de fórmula (I).

WO 03/024918 A1

- 1 -


INTERMEDIATE COMPOUNDS FOR THE PREPARATION OF
MIRTAZAPINE AND OBTENTION METHODS THEREOF

5 Field of the invention

This invention relates to a method for obtaining intermediate compounds useful in the preparation of the pharmaceutical active ingredient mirtazapine, as well as new intermediate compounds for said
10 purpose.

State of the art

Mirtazapine is the international common denomination (ICD) of
15 compound 1,2,3,4,10,14b-hexahydro-2-methylpirazin[2,1-a]pyrindine[2,3-c][2]benzazepine, of formula




20 which is an antidepressive active ingredient first described in German patent application No. 2.614.406, published in 1976.

An important synthesis intermediate for the preparation of mirtazapine, which contributes structurally to a large part of the molecule thereof, is compound (±)-3-phenyl-1-methylpiperazine, of formula

25


- 2 -



whereby an industrially advantageous production of said intermediate compound greatly conditions the industrial efficiency and costs of the preparation of the actual mirtazapine.

Example 4 of US patent No. 4.772.705 describes a method for obtaining (±)-3-phenyl-1-methylpiperazine, which is summarised in the reaction sequence indicated in the following diagram.

10



Thus, the derivate of oxo-piperazine (3) is reduced with aluminium and lithium hydride (LiAlH_4), in ethylic ether for 20 hours, to give the reduced compound (2) which, subsequently, undergoes methylation with methyl iodine (ICH_3) highly dissolved in acetone so that, after additional processing, the (±)-3-phenyl-1-methylpiperazine (1) is isolated in the form of the dihydrochloride thereof.

The starting compound (3) can be obtained, in turn, from phenylacetic acid, through bromation and esterification thereof until the ethyl α -bromophenylacetate is obtained, as described in Schwenk et al. J. Am. Chem. Soc. 70, 3626 (1948), and the bromoester obtained, through reaction with ethylenediamine, leads to the obtention of the mentioned

- 3 -

starting compound (3), as described in Roderick et al. J. Med. Chem. 9(2), 181-5 (1966).

The summarised method has several drawbacks, such as for example the need to use reagents like bromine and methyl iodine and solvents like chlorobenzene, which are highly toxic products, with the main drawback being the fact that in the final methylation stage it is very difficult to apply controls to avoid the formation of large amounts of N,N'-dimethylated compound and methylated compound in the unwanted nitrogen. This explains the low yields obtained despite working in high dissolution conditions, which introduces a further drawback in the handling of large amounts of solvent, with the consequent increase in cost, low efficiency per reaction volume and the need to recover the solvents.

The method that is the object of the invention overcomes such problems because it makes it possible to univocally obtain the correct N-methylated product by means of a simple method that does not require the use of reagents that are highly toxic and difficult to handle.

Object of the invention


The object of the invention is a method for obtaining the compound (\pm)-3-phenyl-1-methylpiperazine, an intermediate for preparing mirtazapine, in which the final step consists of the formation of the piperazine ring.

Also forming part of the object of the invention are new intermediate compounds whose reduction and cyclation enable the compound (\pm)-3-phenyl-1-methylpiperazine to be obtained directly, as well as a method for obtaining said new intermediate compounds.

Description of the invention

The inventors in this case have discovered that the compound (\pm)-3-phenyl-1-methylpiperazine can be obtained when a compound of general formula (I)

- 4 -



in which Z is a leaving group, undergoes a cyclation reaction in the presence of a reducing agent.

5 For the purposes of this invention the leaving group is understood to be a chemical group capable of undergoing a nucleophilic displacement in the nucleophilic substitution reaction generated by the actual piperazine ring of compound (\pm)-3-phenyl-1-methylpiperazine. The leaving groups capable of undergoing a nucleophilic displacement are well known to the
 10 person skilled in the art, and they include, although not exclusively, the following: halogen (fluorine, chlorine, bromine, iodine); alkylsulphonyloxy, possibly substituted, (mesyloxy, triflate, ...) or arylsulphonyloxy, possibly substituted (besyloxy, tosyloxy, ...); hydroxy or alkoxy; thiol or alkylmercapto; etc.

15 Preferably, the reduction/cyclation reaction uses a borane as reducing agent, for example borane (BH_3) or the complex thereof with tetrahydrofuran (THF), or diborane (B_2H_6).


The bibliography contains descriptions of reduction methods which can be used to carry out the method that is the object of this invention. So,
 20 for example, in Brienne et al. Eur. J. Med. Chem. - Chimica Therapeutica, 16(4), 363-6 (1981) describes a reduction method that uses $\text{BH}_3\cdot\text{THF}$ as the reducing agent, which is a commercially available complex consisting of borane and tetrahydrofuran, and which can also be obtained by dissolving diborane in said solvent.

25 US patent No. 5.681.962, example 2, also describes a reduction method that can be used in the method that is the object of the invention, in which borane is produced "*in situ*" from sodium boro-hydride (NaBH_4) and hydrogen chloride in dimethoxyethane (DME). Alternatively, in this method, other strong mineral acids can be used instead of hydrogen chloride


- 5 -

(hydrochloric acid), for example, sulphuric acid, or Lewis acids, with boron trifluoride (BF₃) being preferable in the complex thereof with ethylic ether (boron trifluoride ethyletherate) which is commercially available and can be handled comfortably without any problems.

- 5 US patent No.5.378.729 provides a general description of compounds that can be assigned to the general formula




- 10 including the compounds of general formula (I), the object of the invention, when the following meanings foreseen in said patent are applied: R short chain alkyl group; R₁ short chain alkyl group substituted with an electron attracting group; R₂ hydrogen; R₃ phenyl; and n = 1. Example 4 of US
 15 methylamide, of formula



- 20 which is the closest to the compounds of general formula (I) out of those explicitly described in said patent. However, said patent does not explicitly describe any of the products that can be assigned to general formula (I).


- Consequently, the compounds of general formula (I) are new and form part of the object of this invention. The preferred compounds are those in which Z is halogen, with the compound 2-chloroacetamide-N-methyl-2-
 25 phenylacetamide being particularly preferable, of formula

- 6 -



The compounds of formula (I) have a chiral centre, whereby they can appear in the form of racemic mixtures, mixtures enriched in one of the two enantiomers thereof and even in the form of any of the two pure enantiomers thereof. It must be understood that all the forms mentioned are included in the object of this invention.

The compounds of formula (I) can be prepared by means of a method based on the following synthesis diagram.



Thus, an amidation reaction is produced between 2-amino-2-phenyl-(N-methyl)acetamide (II) and acid (III), in which Z has the afore-mentioned meaning. Preferably, acid (III) is activated prior to the amidation reaction using known techniques, such as the formation of acid halides, anhydrides, mixed anhydrides, active esters, etc., or said acid (III) is used directly employing a coupling agent, such as for example dicyclohexylcarbodiimide (DCC).

Preferably, the amidation reaction of (II) is carried out through reaction with the chloride of monochloroacetic acid in the presence of a hydrochloric acid accepting base, for example sodium carbonate.

Resolving the racemic mixtures of formula (I) compounds into the enantiomers thereof can be carried out using conventional methods, well

- 7 -

known to the person skilled in the art, such as for example chromatography techniques. The pure enantiomers can also be obtained directly by means of stereospecific synthesis.

Compound 2-amino-2-phenyl-(N-methyl)acetamide of formula (II) is known and is described in the literature, as well as methods for the obtention thereof. For example, the compound of formula (II) can be obtained by means of the methods described in the following publications:

Cortés et al. J. Med. Chem. 28, 601-606 (1985),


Feenstra et al. Tetrahedron 46(5), 1745-1756 (1990),

10 and

Jacquier et al. Bull. Soc. Chim. France 3, 1040-1052

(1971),

which are based on the following synthesis diagram:




In other words, an ester, preferably methyl or ethyl, of DL-α-phenylglycine is reacted with methylamine to obtain compound (II). The esters of DL-α-phenylglycine can be obtained easily by means of general methods for the obtention of amino acid esters such as, for example, that described in Akhlaq et al. J. Org. Chem. 27, 4527-45231 (1962).

The following examples are offered to provide the person skilled in the art with a sufficiently clear and complete explanation of this invention, but should not be considered as limitations to the essential aspects of the object thereof, as they have been explained in the earlier sections of this specification.

Examples

30 Example 1 Obtaining methyl DL-α-phenylglycinate hydrochloride (IV)

- 8 -




DL- α -phenylglycine (394.7 g, 2.611 mol) and a solution of methanol/HCl 4.3 N (3940 mL, 16.942 mol) were placed in a 5 L glass reactor and the granulate suspension was stirred at room temperature ($20^{\circ} \pm 2^{\circ}$ C) for 18 hours, with its conversion into a clear solution being observed after approximately 4 hours and its conversion into a cloudy solution (fine suspension) after 8-10 hours. The mixture was concentrated at reduced pressure to an approximate volume of 1,0 L, with approximately 3.3L having been distilled. In this way, a thick, white suspension was obtained which was cooled to $20^{\circ} \pm 1^{\circ}$ C and was filtered, with the filter being washed with methanol (300 mL). The resulting solid was dried at 60° C and atmospheric pressure to constant weight (455,8 g). The filtrate was concentrated again under reduced pressure to an approximate volume of 135 mL, with approximately 600 mL having been distilled. The thick, natural coloured suspension was cooled to $20^{\circ} \pm 1^{\circ}$ C and was filtered, with the filter being washed with methanol (50 mL). The resulting solid was dried at 60° C and atmospheric pressure to constant weight (40.4 g). Both solids contained the title product (IV) (496.2 g, 94.3% yield).

^1H NMR (200-MHz, CD_3OD) δ : 4.01 (s, 3 H, CH_3), 5.11 (s, 3 H, NH_3^+), 5.44 (s, 1 H, CH), 7.66 (s, 5 H, Ar-H).

25 Example 2 Obtaining (\pm)-2-amino-2-phenyl-(N-methyl)acetamide (II)


- 9 -



Compound (IV) of the previous example (493.0 g, 2.445 mol) and an aqueous solution of methylamine 35.5%(p/p) (1188.0 mL, 12.226 mol) were placed in a 5 L glass reactor and a slight exothermic reaction of 5° - 6° C was observed. The resulting solution was stirred at 21° ± 1° C for 1.5 hours and was extracted with dichloromethane (5 x 986 mL and 2 x 493 mL) until TLC showed no presence of the desired product in the aqueous phase. The accumulated organic extracts were evaporated at reduced pressure and a thick oily residue was obtained having a yellowish colour and a slightly cloudy appearance, corresponding to the title product (II) (400 g, 99.6% yield).

¹H NMR (200 MHz, CD₃OD) δ: 2.91 (s, 3 H, CH₃), 4.60 (s, 1 H, CH), 5.07 (s, 3 H, NH, NH₂), 7.48-7.61 (abs. compl., 5 H, Ar-H).

Example 3 Obtaining (±)-2-chloroacetamide-N-methyl-2-phenylacetamide (I)



20

Compound (II) obtained in the previous example (395.0 g, 2.405 mol) and acetone (1074 mL) were placed in a 5 L glass reactor and deionised water (1303 mL) was added to the slightly cloudy resulting solution, with a slight exothermic reaction of 6 °C being observed. Then, Na₂CO₃ (153.0 g, 1.443 mol) was added, with a slight exothermic reaction of 2 °C being observed. The resulting whitish suspension was cooled with

-10-

an ice water bath at 0° - 5° C and, for approximately 1 hour without exceeding 5° C, a solution made up of chloroacetyl chloride (III) (201.0 mL, 285.3 g, 2.526 mol) in acetone (735 mL) was slowly added. The addition created vapours and a slight release of gases. The resulting milky suspension was stirred at 0° - 5° C and, after 1.5 hours, Na₂CO₃ (30.6 g, 0.289 mol) and a solution made up of chloroacetyl chloride (38.3 mL, 54.3 g, 0.481 mol) in acetone (140 mL) was added. After a further 1.5 hours, the suspension was concentrated at reduced pressure to a volume of approximately 1.0 L, with approximately 3.0 L having been distilled. The white thick suspension was cooled to 18° ± 2° C and was filtered, with the filter being washed with deionised water (300 mL). A white solid was obtained that was dried at 60° C and at reduced pressure and, which corresponded to the title product (I), having a melting point of 192-194° C (483.7 g, 83.55% yield).


¹H-NMR (300 MHz, DMSO-d₆)δ: 2.57 (d, J= 4.5 Hz, 3 H, CH₃), 4.18 (s, 2 H, CH₂Cl), 5.40 (d, J=7.8 Hz, 1 H, CH), 7.24-7.40 (abs. compl. 5 H, Ar-H), 8.33 (c, J=4.8 Hz, 1 H, NH-CH₃), 8.90 (d, J=8.1 Hz, 1 H, NH-CH).

¹³C-NMR (75.4 MHz, DMSO-d₆)δ: 25.9 (CH₃, NH-CH₃), 42.7 (CH₂, CH₂Cl), 56.6 (CH, NH-CH), 127.8 (CH, Ar-C_{para}), 127.1 and 128.6 (CH, Ar-C_{ortho} and Ar-C_{meta}), 138.7 (C, Ar-C_{ipso}), 165.6 and 169.8 (C, 2 CO-NH).

The product obtained has sufficient quality to be used to obtain (±)-3-phenyl-1-methylpiperazine, but if desired, for analytical purposes, it can be purified by being washed by alternative suspension in acetone and water until a product is obtained having a melting point of 194-195° C with a purity in the region of 99.9% (HPLC).

Example 4 Obtaining (±)-3-phenyl-1-methylpiperazine

-11-



Compound (I) of the previous example (0.5 g, 2.077 mmol) and tetrahydrofuran (5 mL) were placed in a 25 mL flask, and for approximately 10 minutes the $\text{BH}_3\cdot\text{THF}$ complex 1 M (10.4 mL, 10.386 mmol) was added to the white suspension. The resulting colourless solution was heated to reflux temperature for 6.5 hours, it was cooled to $19^\circ \pm 1^\circ \text{C}$ and an aqueous solution of HCl 6 N (1.82 mL) was added slowly. The mixture was distilled at reduced pressure to remove the tetrahydrofuran.

10 Ethyl acetate (5 mL) was added and was extracted with an aqueous solution of HCl 2 N (3 x 5 mL). The accumulated acidic phases were alkalinised with an aqueous solution of NaOH 50% (p/p) to pH 12-13 (1.1 mL), saturated with NaCl (6.25 g) and were extracted with ethyl acetate (3 x 5 mL). The accumulated organic phases were dried with anhydrous


15 Na_2SO_4 , they were filtered and evaporated at reduced pressure, giving a yellowish liquid residue which corresponded to the title product (0.3 g, 81.97%).

$^1\text{H-NMR}$ (300 MHz, CDCl_3) δ : 2.05 (pseudo t, $J=10.7$ Hz) and 2.20 (pseudo dt, $J=11.0$ Hz, $J'=4.4$ Hz) (2H, piperazine-2H), 2.34 (s, 3 H, CH_3), 2.7-3.0 (abs. compl., 3 H, NH and piperazine-2H), 3.04-3.16 (abs. compl., 2 H, piperazine-2H), 3.91 (dd, $J=10.2$ Hz, $J'=2.7$ Hz, 1 H, piperazine-CH), 7.26-7.42 (abs. compl., 5 H, Ar-H).

$^{13}\text{C NMR}$ (75.4 MHz, CDCl_3) δ : 46.0 (CH_2 , C5), 46.1 (CH_3 , N- CH_3), 55.0 (CH_2 , C6), 60.1 (CH, C3), 62.9 (CH_2 , C2), 126.9 and 128.4 (CH, Ar- C_{ortho} and Ar- C_{meta}), 127.5 (CH, Ar- C_{para}), 142.0 (C, Ar- C_{ipso}).

25 ME (IE, direct Introduction, 70 eV), m/z (%): 176 (M^+ , 1), 118 (3), 104 (C_8H_8^+ , 12), 58 ($\text{C}_3\text{H}_8\text{N}^+$, 100).

-12-

Example 5 Obtaining (±)-3-phenyl-1-methylpiperazine


5 NaBH₄ (75.4 g, 1.99 mol) and compound (I) obtained in example 3
 (80 g, 0.332 mol) were placed in a 2 L cylindrical reactor. The mixture was
 cooled to 0° - 5° C with an ice water bath and 1,2-dimethoxyethane (640
 mL) was loaded, with an exothermic reaction of approximately 8° C being
 observed and hardly any gas release. The suspension was cooled to 0° - 5°
 10 C and a solution of 1,2-dimethoxyethane/HCl 6.5 N (297 mL, 1.93 mol)
 was slowly added without exceeding 20° C, with an exothermic reaction
 being observed and an intense gas release. The mixture was heated to 42°
 ± 3° C for 6 hours, it was cooled to 10° - 15° C and an aqueous solution of
 HCl 6 N was added to pH 1 (305 mL), with an exothermic reaction being
 15 observed and an intense gas release. The resulting whitish suspension
 was stirred at 20° ± 2° C for at least 1 hour, it was cooled to 10° - 15° C;
 alkalised with an aqueous solution of NaOH 50% (p/p) to pH 12-14 (170
 mL) and extracted with dichloromethane (3 x 250 mL). The accumulated
 organic phases were evaporated at reduced pressure, giving a yellowish
 20 liquid residue corresponding to the title product (56.33 g, 96.15%).

-13-

CLAIMS

1.- Compound of general formula (I)

5



in which Z is a leaving group capable of undergoing a nucleophilic displacement.

10


2. Compound according to claim 1, characterised in that Z is selected from halogen, alkylsulphonyloxy, possibly substituted, arylsulphonyloxy, possibly substituted, hydroxy, alkoxy, thiol or alkylmercapto.

15

3. Compound according to claim 2, characterised in that Z is a halogen.


4. Compound 2-chloroacetamide-N-methyl-2-phenylacetamide, of formula

20




-14-

5. Method for obtaining the compounds of claims 1 to 4, characterised in that it causes an amidation reaction between compound 2-amino-2-phenyl-(N-methyl)acetamide, of formula (II)



and an acid of formula (III)



in which Z has the meaning indicated above, or with an activated derivate of said acid.

6. Method according to claim 5, characterised in that the activated acid derivate is selected from acid halides, anhydrides, mixed anhydrides and active esters.


7. Method according to claim 6, characterised in that the activated derivate is the chloride of monochloroacetic acid.

8. Method according to any of claims 5 to 7, characterised in that the amidation reaction is carried out in the presence of a base.

-15-

9. Method according to claim 8, characterised in that the base is sodium carbonate.

10. Method for obtaining the compound (\pm)-3-phenyl-1-methylpiperazine, of formula



10 characterised in that one of the compounds defined in claims 1 to 4 undergoes a cyclation reaction in the presence of a reducing agent.

11. Method according to claim 10, characterised in that the reducing agent is a borane.

15

12. Method according to claim 11, characterised in that the reducing agent is the borane and tetrahydrofurane $\text{BH}_3\cdot\text{THF}$ complex.

13. Method according to claim 11, characterised in that the borane is prepared "*in situ*" from sodium boro-hydride and a strong mineral acid or a Lewis acid.

14. Method according to claim 13, characterised in that the strong mineral acid is the hydrogen chloride in 1,2-dimethoxyethane.

25

15. Method according to claim 13, characterised in that the Lewis acid is boron trifluoride (BF_3) in the form of the complex thereof with ethylic ether (boron trifluoride ethyletherate).